product name Marbofloxacin
Description: Marbofloxacin, a carboxylic acid derivative, is a third generation fluoroquinolone antibiotic. It is a synthetic, broad spectrum bactericidal agent that is mainly used in veterinary medicine. The bactericidal activity of marbofloxacin is concentration dependent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure. Like other fluoroquinolones, marbofloxacin has demonstrated a significant post-antibiotic effect for both gram–and + bacteria and is active in both stationary and growth phases of bacterial replication.
References: Vet Parasitol. 2006 Jan 30;135(2):137-46; J Vet Pharmacol Ther. 2006 Dec;29(6):555-60.
362.36
Formula
C17H19FN4O4
CAS No.
115550-35-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 3 mg/mL (8.3 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4: 14 mg/mL
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Marbofloxacin is a fluoroquinolone antimicrobial agent developed exclusively for veterinary use. Marbofloxacin exhibits high bactericidal activity against a broad spectrum of aerobic Gram-negative and some Gram-positive bacteria, as well as Mycoplasma spp. As the third generation fluoroquinolone, Marbofloxacin also mainly targets replication and transcription enzymes such as DNA gyrase and topoisomerase IV, which are both essential for bacterial viability. Marbofloxacin has a mycoplasmacidal effect during the exponential phase but not during the lag phase, in both the M. hyopneumoniae 116 wild-type strain and a clone isolated 4 days post-marbofloxacin treatment in vivo at the therapeutic dose. Marbofloxacin significantly kills Leishmania promastigotes and intracellular amastigotes in a dose-dependent manner, more efficient than meglumine antimoniate and sodium stibogluconate. After treatment with Marbofloxacin, macrophages acquire resistance to infection and enhanced antileishmanial activity through the NO synthase pathway. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Marbofloxacin treatment at the therapeutic dose does not eliminate M. hyopneumoniae, with 87.5 to 100% of the pigs still positive at the end of the assays, and is not effective in significantly reducing clinical signs. Nevertheless, Marbofloxacin treatment seems to decrease the lung lesion scores. Administration of Marbofloxacin at 6 mg/kg once daily for 7 days in a Staphylococcus aureus infection in tissue cages in ponies is not effective for the elimination of S. aureus infections from secluded sites. |
| Animal model | SPF piglets inoculated intratracheally with M. hyopneumoniae strain 116 |
| Formulation & Dosage | Dissolved DMSO, and diluted in saline; 2 mg/kg/day; i.m. injection |
| References | Vet Parasitol. 2006 Jan 30;135(2):137-46; J Vet Pharmacol Ther. 2006 Dec;29(6):555-60. |
